Ixekizumab (Taltz™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about ixekizumab for the treatment of ankylosing spondylitis.
You can give input if you are a B.C. resident and have ankylosing spondylitis, a caregiver to someone with ankylosing spondylitis, or if your group represents people who live with ankylosing spondylitis.
If you would like our help in providing your input, you can email your comments to email@example.com or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Wednesday, February 12 so that we may submit the questionnaire in time for the deadline.
The submission deadline is midnight on February 19, 2020. Patients and caregivers may give their input directly through the links below.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for ixekizumab for the treatment of ankylosing spondylitis: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)